Antipsychotics as antidepressants: What is the mechanism?

Psychiatria Danubina

Volumn 23, Issue 3, 2011, Pages 302-307

  Šagud, Marina ^a   Mihaljević Peleš, Alma ^a   Begić, Dražen ^a   Vuksan Ćusa, Bjanka ^a   Kramarić, Milivoj ^a   Živković, Maja ^b   Jakovljević, Miro ^a  

^a KBC Zagreb   (Croatia)

^b Neuropsihijatrijska bolnica   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ALPHA ADRENERGIC RECEPTOR; AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; HALOPERIDOL; HYDROCORTISONE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; TIANEPTINE; ZIPRASIDONE;

CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; HEART CONDUCTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERPROLACTINEMIA; MAJOR DEPRESSION; MONOTHERAPY; NEUROTRANSMISSION; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLEEP PARAMETERS;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; HYDROCORTISONE; NERVE GROWTH FACTORS; RECEPTORS, BIOGENIC AMINE; SLEEP; TREATMENT OUTCOME; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 80054118266     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 2009; 205:119-28.
2. Aripiprazole prescribing information, 2008; www.FDA.gov
3. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004; 65:975-81.
4. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70:540-9.
5. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007; 22:1-9.
6. Begić D, Mahnik-Miloš M, Grubišin J. EEG characteristics in depression, "negative" and "positive" schizophrenia. Psychiatria Danubina 2009; 21:579-584.
7. Blier P, Blondieau C. Neurological bases and clinical aspects of the use of aripiprazole in treatment-resistant depressive disorder. J Affect Dis 2011; 128(suppl 1): 3-10.
8. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, Earley W, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011; 128:83-94.
9. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 1999; 37:107-22.
10. Cassano GB, Jori MC. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2002; 17:27-32.
11. Chen J, Gao K, Kemp DE. Second-generation Antipsychotics in Major Depressive Disorder: Update and Clinical Perspective. Curr Opin Psychiatry 2011; 24:10-17.
12. Cohrs S, Meier A, Neumann AC, Jordan W, Rüther E, Rodenbeck A. Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. J Clin Psychiatry 2005; 66:989-96.
13. Cohrs S, Röher C, Jordan W, Meier A, Huether G, Wuttke W, Rüther E, Rodenbeck A. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) 2006; 185:11-8.
14. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry 2009; 70:526-39.
15. Dhir A, Kulkarni SK. Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. Neurosci Lett 2008; 445:83-8.
16. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry godina; 68: 1071-1077.
17. Gedge L, Lazowski L, Murray D, Jokic R, Milev R. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatr Dis Treat 2010; 6:501-8.
18. Gillin JC, Mendelson WB, Kupfer DJ. The sleep disturbances of depression: Clues to the pathophysiology with special reference to the circadian rapid exe movement rhythm. In: Kupfer DJ, Monk TH. (eds.) Biological rhythms and mental disorders. New York: Guilford Press, 1988.
19. Giménez S, Clos S, Romero S, Grasa E, Morte A, Barbanoj MJ. Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers. Psychopharmacol 2007; 190:507-516.
20. González-Pinto A, Mosquera F, Palomino A, Alberich S, Gutiérrez A, Haidar K, Vega P, Barbeito S, Ortiz A, Matute C Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int Clin Psychopharmacol 2010; 25: 241-5.
21. Hedlund PB. The 5HT7 receptor and disorders of the nervous system: an overview. Psychopharmacol 2009; 206:345-354.
22. Hubain PP, Souery D, Jönck L, Staner L, Van Veeren C, Kerkhofs M, Mendlewicz J, Linkowski P. Relationship between the Newcastle scale and sleep polysomnographic variables in major depression: a controlled study. Eur Neuropsychopharmacol 1995; 5:129-34.
23. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008; 33:2303-12.
24. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010 Dec 8;(12):CD008121. Review.
25. Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S. Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol 2011; 1-9. [Epub ahead of print]
26. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999; 288:774-781.
27. Lavergne F, Jay TM: A new strategy for antidepressant prescription. Frontiers in neuroscience 2010; 4, 192:1-13.
28. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 2010; 27:964-76.
29. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007; 24:487-94.
30. Minzenberg JM, Yoon JH. An index of relative central α-adrenergic receptor antagonism by antipsychotic medication. Exp Clin Psychopharmacol 2011; 19:31-39.
31. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5.hydroxytryptamine 2c receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharm Exp Ther 2003; 306:954-964.
32. Mørk A, Witten LM, Arnt J.Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology 2009; 206:39-49.
33. Musazzi L, Cattaneo A, Tardito D, Barbon A, Gennarelli M, Barlati S, Racagni S, Popoli M. Early rise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. Biol Psychiatry 2009; 10:48.
34. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry 2007; 68 (Suppl 8):17-25.
35. Olanzapine prescribing information 2009; www.FDA.gov
36. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65:217-21.
37. Quetiapine prescribing information, www1.astrazeneca-us.com/pi/ seroquelxr.pdf 2011.
38. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Those ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905-17.
39. Sagud M, Mihaljević-Peles A, Muck-Seler D, Jakovljevic M, Pivac N Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology (Berl). 2006 Sep; 187:511-512.
40. Schechter LE, Bolaños FJ, Gozlan H, Lanfumey L, Haj-Dahmane S, Laporte AM, Fattaccini CM, Hamon M. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J Pharmacol Exp Ther 1990; 255:1335-47.
41. Schechter LE, Lin Q, Smith DL, Zhang G, Shan Q, Platt B, Brandt MR, Dawson LA, Cole D, Bernotas R, Robichaud A, Rosenzweig-Lipson S, Beyer CE (2008) Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 33:1323-1335.
42. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425:197-201.
43. Schwartz TL, Stahl SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neurosci Ther 2011; 17:110-7.
44. Sen S, Duman R, Sanacora G. Serum BDNF, depression and anti-depressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64:527-532.
45. Sharpley AL, Elliott JM, Attenburrow MJ, Cowen PJ. Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 1994; 33:467-71.
46. Sharp ley AL, Attenburrow ME, Hafizi S, Cowen PJ. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 2005; 66:450-4.
47. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66:1289-97.
48. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med 2011; 73:114-26.
49. Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368:277-83.
50. Those ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dubé S. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68:224-36.
51. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H; Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009; 14:299-313.
52. Wesolowska A. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of clinical data. Pharmacol Rep 2010; 62:564-77.
53. Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Katsuki A, Hayashi K, Ueda N, Nakamura J. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:308-12.